Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

Hendrik Nolte; Henrik Harving; Vibeke Backer

Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

Translated title of the contribution: Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine

Hendrik Nolte, Henrik Harving, Vibeke Backer

Abstract

Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.

Translated title of the contribution	Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	169
Issue number	50
Pages (from-to)	4366-7
Number of pages	2
ISSN	0041-5782
Publication status	Published - 10 Dec 2007
Externally published	Yes

Cite this

@article{466f465e653e41819862dbf77b55a57f,

title = "Behandling af sv{\ae}r astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi",

abstract = "Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.",

keywords = "Adult, Anti-Asthmatic Agents/administration & dosage, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal, Humanized, Asthma/drug therapy, Drug Therapy, Combination, Female, Humans, Male, Omalizumab, Treatment Outcome",

author = "Hendrik Nolte and Henrik Harving and Vibeke Backer",

year = "2007",

month = dec,

day = "10",

language = "Dansk",

volume = "169",

pages = "4366--7",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "50",

}

TY - JOUR

T1 - Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

AU - Nolte, Hendrik

AU - Harving, Henrik

AU - Backer, Vibeke

PY - 2007/12/10

Y1 - 2007/12/10

N2 - Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.

AB - Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.

KW - Adult

KW - Anti-Asthmatic Agents/administration & dosage

KW - Antibodies, Anti-Idiotypic

KW - Antibodies, Monoclonal/administration & dosage

KW - Antibodies, Monoclonal, Humanized

KW - Asthma/drug therapy

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Male

KW - Omalizumab

KW - Treatment Outcome

M3 - Tidsskriftartikel

C2 - 18211797

SN - 0041-5782

VL - 169

SP - 4366

EP - 4367

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 50

ER -

Behandling af svær astma med anti-immunglobulin E (omalizumab). En ny mulighed i lungemedicinsk regi

Abstract

Fingerprint

Cite this